Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona Wightman

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Retrovirology|October 14, 2011
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cellsSuha Saleh, Fiona Wightman, Saumya Ramanayake, et al.
AIDS (London, England)|July 18, 2009
The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cellsMiranda Shehu-Xhilaga, David Rhodes, Fiona Wightman, et al.
Hepatology (Baltimore, Md.)|October 10, 2007
The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infectionJ Judy Chang, Alexander J V Thompson, Kumar Visvanathan, et al.
Plos One|July 8, 2016
Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In VitroJenny L Anderson, Talia M Mota, Vanessa A Evans, et al.
AIDS (London, England)|November 6, 2013
Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cellsFiona Wightman, Hao K Lu, Ajantha E Solomon, et al.
Journal of Virology|January 8, 2010
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapyMegan Crane, Sunee Sirivichayakul, J Judy Chang, et al.
The Journal of Infectious Diseases|October 29, 2010
Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapyFiona Wightman, Ajantha Solomon, Gabriela Khoury, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2008
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infectionSharon R Lewin, John M Murray, Ajantha Solomon, et al.
Plos One|November 20, 2014
Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapyHao K Lu, Lachlan R Gray, Fiona Wightman, et al.
Journal of Virology|April 2, 2010
Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigenDavid M Iser, Nadia Warner, Peter A Revill, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Retrovirology|October 14, 2011
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cellsSuha Saleh, Fiona Wightman, Saumya Ramanayake, et al.
AIDS (London, England)|July 18, 2009
The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cellsMiranda Shehu-Xhilaga, David Rhodes, Fiona Wightman, et al.
Hepatology (Baltimore, Md.)|October 10, 2007
The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infectionJ Judy Chang, Alexander J V Thompson, Kumar Visvanathan, et al.
Plos One|July 8, 2016
Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In VitroJenny L Anderson, Talia M Mota, Vanessa A Evans, et al.
AIDS (London, England)|November 6, 2013
Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cellsFiona Wightman, Hao K Lu, Ajantha E Solomon, et al.
Journal of Virology|January 8, 2010
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapyMegan Crane, Sunee Sirivichayakul, J Judy Chang, et al.
The Journal of Infectious Diseases|October 29, 2010
Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapyFiona Wightman, Ajantha Solomon, Gabriela Khoury, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2008
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infectionSharon R Lewin, John M Murray, Ajantha Solomon, et al.
Plos One|November 20, 2014
Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapyHao K Lu, Lachlan R Gray, Fiona Wightman, et al.
Journal of Virology|April 2, 2010
Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigenDavid M Iser, Nadia Warner, Peter A Revill, et al.
Pageof 3